A position statement published more than a decade ago by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) approved the use of DPP-4 inhibitors and GLP-1R agonists in treatment of type 2 diabetes and as second-line agents for treatment of poor glycemic control [63]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.